Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) have received an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $50.00.

A number of research analysts recently issued reports on the company. Cantor Fitzgerald dropped their price target on Zai Lab from $55.00 to $37.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zai Lab in a research note on Wednesday, January 21st. UBS Group began coverage on Zai Lab in a report on Wednesday, January 7th. They issued a “buy” rating and a $35.00 price objective for the company. JPMorgan Chase & Co. lowered their target price on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Finally, Jefferies Financial Group upgraded shares of Zai Lab to a “strong-buy” rating in a research report on Monday, January 19th.

Zai Lab Price Performance

Shares of ZLAB opened at $18.81 on Wednesday. Zai Lab has a 1-year low of $15.96 and a 1-year high of $44.34. The stock has a market cap of $2.12 billion, a PE ratio of -11.68 and a beta of 0.85. The firm has a fifty day moving average price of $18.56 and a 200 day moving average price of $21.93.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($0.50) earnings per share (EPS) for the quarter. Zai Lab had a negative return on equity of 22.81% and a negative net margin of 38.15%.The firm had revenue of $127.60 million for the quarter. As a group, equities analysts expect that Zai Lab will post -2.58 EPS for the current fiscal year.

Insider Buying and Selling at Zai Lab

In other news, insider Rafael Amado sold 2,957 shares of the stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $18.63, for a total transaction of $55,088.91. Following the completion of the sale, the insider owned 44,757 shares in the company, valued at approximately $833,822.91. This represents a 6.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Joshua L. Smiley sold 1,966 shares of the firm’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $18.63, for a total value of $36,626.58. Following the transaction, the insider directly owned 91,026 shares in the company, valued at approximately $1,695,814.38. This represents a 2.11% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 6,626 shares of company stock valued at $123,442. Company insiders own 4.96% of the company’s stock.

Institutional Trading of Zai Lab

An institutional investor recently bought a new position in Zai Lab stock. SG Americas Securities LLC bought a new stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 9,754 shares of the company’s stock, valued at approximately $331,000. 41.65% of the stock is owned by hedge funds and other institutional investors.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.